We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Relmada Therapeutics Inc | NASDAQ:RLMD | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.06 | -1.93% | 3.05 | 2.93 | 35.00 | 3.12 | 2.96 | 3.12 | 92,014 | 05:00:06 |
NEW YORK, May 12, 2023 /PRNewswire/ -- Jakubowitz Law announces that an investigation into potential securities fraud allegations has commenced on behalf of shareholders of Relmada Therapeutics, Inc. (NYSE: RLMD)
To be contacted by a member of our team, fill out the form:
https://claimyourloss.com/securities/relmada-class-action-loss-submission-form/?from=4
Further details on the investigation: Before market opened on October 13, 2022, Relmada announced the results of its RELIANCE III study (REL-1017-303), evaluating the drug REL-1017 as a monotherapy for Major Depressive Disorder (MDD). Relmada revealed that the RELIANCE III trial did not achieve its primary endpoint, which was a statistically significant improvement in depression symptoms compared to placebo on Day 28, as measured by the Mongomery-Asberg Depression Rating Scale (MADRS). Specifically, the REL-1017 treatment showed a MADRS reduction of 14.8 points at Day 28 versus 13.9 points for placebo, a higher-than-expected placebo response. Relmada described that "[p]aradoxical results were observed in certain study sites, where placebo dramatically outperformed REL-1017."
Following this news, Relmada's stock price fell nearly 80% to close at $6.48 per share on October 13, 2022.
Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (628) 895-0423
F: (212) 537-5887
View original content:https://www.prnewswire.com/news-releases/rlmd-fraud-alert-jakubowitz-law-is-investigating-relmada-therapeutics-inc-in-connection-with-potential-violations-of-federal-securities-laws-301815633.html
SOURCE Jakubowitz Law
Copyright 2023 PR Newswire
1 Year Relmada Therapeutics Chart |
1 Month Relmada Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions